Journal
JOURNAL OF CROHNS & COLITIS
Volume 8, Issue 2, Pages 166-171Publisher
OXFORD UNIV PRESS
DOI: 10.1016/j.crohns.2013.09.007
Keywords
Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Thrombosis; Venous thromboembolic disease
Categories
Funding
- National Institute for Health Research [CL-2013-13-008] Funding Source: researchfish
Ask authors/readers for more resources
Inflammatory bowel disease (IBD) is a disease-specific risk factor for incident and recurrent venous thromboembolism (VTE). The reasons are acquired, multifactorial, and related to prothrombotic aberrations during active disease, although the mechanisms remain incompletely elucidated. VTE represents a potentially life-threatening extraintestinal manifestation of IBD, but the associated morbidity and mortality can be reduced by appropriate use of thromboprophylaxis. Nevertheless, despite international guidelines advocating thromboprophylaxis in hospitalised patients with IBD, practice is highly variable, since 65% of gastroenterologists may not use pharmacological VTE prophylaxis in hospitalised patients with acute severe colitis. Furthermore, there is no guidance on appropriate prophylaxis for ambulatory outpatients with active disease who are at an appreciable risk of VIE. Thus the question: are we tailoring thromboprophylaxis to those patients with IBD who are most at risk? (C) 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available